Home Insider News Insider Selling Report: Horizon Therapeutics Public Limited Company 's EVP, Chief HR...

Insider Selling Report: Horizon Therapeutics Public Limited Company [HZNP]’s EVP, Chief HR Off, Konstantinovsky Irina, Sells 26,844 Shares

On Jan. 06, Konstantinovsky Irina divested U.S. $2,006,854 in shares of Horizon Therapeutics Public Limited Company. The EVP, Chief HR Off sold 26,844 shares at a price per share of $74.76. The transaction decreased this specific insider’s holdings to 86,499 shares worth around $6.88 million at present.

Another 27,106 shares were sold by Desjardin Michael A., for more than $2,032,950 in total proceeds. The EVP, Technical Operations dumped the shares at a price of $75.00 and the insider now owns almost 114,662 shares.

5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored

That same day, Karnani Vikram sold 30,031 shares. The EVP, Pres, International divested U.S. $2,252,325 in shares of Horizon Therapeutics Public Limited Company at a price per share of $75.00. The transaction decreased this specific insider’s holdings to 111,429 shares worth around $8863062.66 at present.

JP Morgan launched its Horizon Therapeutics Public Limited Company [HZNP] rating to the equivalent of an Overweight and assigned the price target of $110, in a research note dated September 09, 2020. That figure represents around a 27.69% premium from where the company’s shares closed on Friday. Some new analysts also started their coverage, with JP Morgan’s analysts assigning the shares to “an Overweight” rating in a research note to investors issued in early September. Meanwhile, Citigroup had launched its coverage on HZNP with “Buy”, in a research note produced for clients August 27, 2020. In addition, there was a new coverage from Goldman on January 08, 2020. The research firm rated HZNP “a Neutral”.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Is Horizon Therapeutics Public Limited Company [NASDAQ:HZNP] a Good Buy Right Now?

It should be noted that HZNP technical indicators for short, intermediate as well as long term progress have placed an overall average of 72% as Buy. The average signal changed from 24% Buy in the last week and compares with 24% Buy in the past month. Data from Horizon Therapeutics Public Limited Company’s Trend Spotter indicated that the signals were Strengthening. The stock current average is 2.74 million shares in the past 20 days and the short term average signal indicates a 50% Buy. In the last 50 days, the average trading volume was 2.81 million shares while the medium term average advocated for 50% Buy. The average long-term signal stands at 100% Buy and the 100-day average volume stands at 2.39 million shares.

HZNP Price Performance

On Wall Street, Horizon Therapeutics Public Limited Company [NASDAQ:HZNP] finished Friday’s session down -0.08% at $79.54. The stock went up to $80.58 at the same session while its lowest single day price was $78.0297. In the last five days, it saw a rise of about 8.74%, Horizon Therapeutics Public Limited Company shares gained by almost 8.74% since the beginning of the year. However, the share price has dropped to as low as -8.23% below its one year high. On 01/08/21, the company shares recorded $80.58, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/04/21, the same year at $70.88. The company’s shares have inclined by 119.24% in the past year. The 50-day SMA achieved is $72.61 while the 200-day SMA is $61.76. Volume dropped to 1.8 million from 2.03 million in the previous session.

Horizon Therapeutics Public Limited Company [HZNP] Valuation Measures

Notably, Horizon Therapeutics Public Limited Company [HZNP] stock can be classified as a good candidate in the listing of underestimated low-priced Drug Manufacturers – General companies to purchase soonest possible with the prevailing 12-month PE ratio of 21.72. The measure means the stock is exchanging at a discount as compared to the 24.35x trailing earnings of the industry. It can be helpful for investors to consider historical price-sales ratio, more specifically, a 9.66 PS value ratio is reported for the last one year of reported earnings. That is higher than the industry average of 2.89 which means HZNP serve an attractive investment opportunity compared to its competitors.

HZNP Stock Support And Resistance Levels

On the 24-hour scale, the immediate backing is perceived around 78.19 level, and in case of violation of this particular level, it will cause more drop to 76.83 level. On the upper level, 81.93 is still the key resistance. The stock may increase to the subsequent resistance at 80.74. The Relative Strength Index (RSI) pinned on the 14-day chart is 65.90, implying a neutral technical stance while the MACD stands at 6.17, meaning price will increase in the next trading period. Percent R indicator moved to 7.34%, implying bullish price movement. Stochastic %K at 89.97% suggest selling the stock.

What is the short interest in Horizon Therapeutics Public Limited Company?

Short interest in the Horizon Therapeutics Public Limited Company stock has plunged, decreasing by -2.61 million shares to total 8.91 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 6.3 million, data from Yahoo Finance shows. The increase of 29.29% suggests the stock saw some increased bearish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 4.09% of the overall float for the stock.

Horizon Therapeutics Public Limited Company’s Biggest Shareholders: Who Owns Horizon Therapeutics Public Limited Company [HZNP]?

Filings by The Vanguard Group, Inc. showed that the firm now holds a total of 18,940,305 shares or roughly 8.58% of the outstanding HZNP shares. This means their shares have increased by 1,493,761 from the 18,940,305 the investor reportedly held in its prior 13-F filing. With the conclusion of the purchase, Fidelity Management & Research Co updated stake is worth $1,132,313,252. Details in the latest 13F filings reveal that BlackRock Fund Advisors acquired their 1.74% stake valued at $738,788,374 while Janus Capital Management LLC added theirs at $629,514,116. During the last quarter, BlackRock Fund Advisors raised 179,606 of its shares in Horizon Therapeutics Public Limited Company while Janus Capital Management LLC bought 580,629 shares. The Renaissance Technologies LLC’s holdings currently number 8,780,875 shares at $698430797.5. According to the firm’s last 13F report, Avoro Capital Advisor LLC shares in the company at filing stood at 7,650,000 shares, roughly $538,789,500.

HZNP Earnings Forecast For The Current Quarter

Horizon Therapeutics Public Limited Company [HZNP] is expected to report strong earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $678.3M and an earnings per share of $1.02 for Dec 2020. Looking further ahead, the company is expected to report revenue of $478.16M at an EPS of $0.53 for Mar 2021. The estimates represent upside of 27.30% and 18.91% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.

HZNP Earnings Estimates For The Current Year

For the financial year, Horizon Therapeutics Public Limited Company [NASDAQ:HZNP] is expected to bring in revenue of $2.13B. The returns are nearly $830.0 million higher than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at 3.61, higher than that of FY19 by $1.67. Estimates put this year’s earnings growth at 86.10%, 18.80% for the next, and at an annual 30.20% over the next 5-year period. As for sales, forecasts are for an increase of 64.10% in the current fiscal year and a further 27.30% over the following year.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

What are analyst thoughts on Horizon Therapeutics Public Limited Company?

Looking forward to the Horizon Therapeutics Public Limited Company share price prediction, we can see that analysts, surveyed by FactSet, offer the mean price target for Horizon Therapeutics Public Limited Company stock at $108.00 within the next 12 months, which represents almost 26.35 per cent growth from its previous closing price of $79.54. The highest analysts’ target for Horizon Therapeutics Public Limited Company stock projections is $123.00 and the lowest one is $81.00. Still, 11 analysts sharing their consensus rating for HZNP stock in 2021 agree that it is a Buy.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Torchlight Energy Resources Inc. (TRCH) stock surged during current market trading. Here’s to know why?

Torchlight Energy Resources Inc. (NASDAQ: TRCH) stock gained by 41.33% in the current market trading session. Torchlight Energy Resources is a vast growing oil...

The9 Ltd. (NCTY) stock declined during pre-market trading. Here’s the update

The9 Ltd. (NASDAQ: NCTY) stock plunged by 12% at the last close while the NCTY stock price fell by 7.03% during pre-market trading. The9...

The Dixie Group Inc. (DXYN) stock surged during pre-market trading given no recent news

The Dixie Group Inc. (NASDAQ: DXYN) stock gained by 11.55% in the pre-market trading session. However, there is no update available regarding this hike...

Why BancorpSouth Bank (BXS) stock plummeted on Friday?

BancorpSouth Bank (BXS) shares plummeted 9.39% in after-hours on Friday, June 18, 2021, and close the weekly business at $25.00 per share. Earlier, BXS's...

CureVac Inc. (CVAC) stock soar during pre-market trading. Here’s what you should know?

CureVac Inc. (NASDAQ: CVAC) stock declined by 38.99% at the last close while the CVAC stock price gains by 11.34% in the pre-market trading...

Anavex Inc. (AVXL) stock soars during pre-market trading. Let’s see why?

Anavex Inc. (AVXL) stock gained by 4.29% at the last close while the AVXL stock price surged by 12.38% in the pre-market trading session....

The9 Ltd. (NCTY) stock declined during pre-market trading. Here’s the update

The9 Ltd. (NASDAQ: NCTY) stock plunged by 12% at the last close while the NCTY stock price fell by 7.03% during pre-market trading. The9...

The Dixie Group Inc. (DXYN) stock surged during pre-market trading given no recent news

The Dixie Group Inc. (NASDAQ: DXYN) stock gained by 11.55% in the pre-market trading session. However, there is no update available regarding this hike...

Related News

The Aqua Metals (AQMS) Stock Is An Pre-Market Upsurge of 13% For What Reason?

The metal recycling firm Aqua Metals, Inc. (NASDAQ: AQMS) is on an uptick today in premarket session. As of 09:08 a.m. EST, the stock...

Insider Selling Report: Nu Skin Enterprises Inc. [NUS]’s Pres, Napierski Ryan S, Sells 4,844 Shares

On Jan. 07, Napierski Ryan S divested U.S. $286,038 in shares of Nu Skin Enterprises Inc.. The Pres sold 4,844 shares at a price...

Insider Alert: Harmonic Inc. [HLIT]’s SVP, Video R, D, Haltmayer Neven, Makes A $117,240 Sell

On Jan. 06, Haltmayer Neven divested U.S. $117,240 in shares of Harmonic Inc.. The SVP, Video R, D sold 15,632 shares at a price...

ACM Research Inc. [ACMR] Sees 2,000 Share Insider Sell From Dir Liu Tracy

On Jan. 06, Liu Tracy divested U.S. $200,000 in shares of ACM Research Inc.. The Dir sold 2,000 shares at a price per share...

Insider Selling: MasTec Inc. [MTZ] CFO Sells 30,027 Shares Worth $2,404,436

On Jan. 07, Pita George divested U.S. $2,404,436 in shares of MasTec Inc.. The CFO sold 30,027 shares at a price per share of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam